Oramed Pharmaceuticals Inc.

As of June 30, 2026, Oramed Pharmaceuticals Incorporated carries a market capitalization of 57.92B, placing it among publicly traded companies globally. Its enterprise value stands at 43.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Oramed Pharmaceuticals Incorporated's next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Oramed Pharmaceuticals Incorporated has 41.31M shares outstanding.

As of June 30, 2026, Oramed Pharmaceuticals Incorporated trades at a trailing price-to-earnings ratio of 1.11.

As of June 30, 2026, Oramed Pharmaceuticals Incorporated maintains a current ratio of 4.98, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Oramed Pharmaceuticals Incorporated posted a return on equity (ROE) of 74.10, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -4.81, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 65.82, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 73.99, useful for judging operating efficiency across full business cycles. The company generates approximately - - in revenue per employee across its workforce of 13.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Oramed Pharmaceuticals Incorporated recorded 13.46B in income tax expense. That works out to an effective tax rate of 20.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 65.29B, leaving 51.83B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Oramed Pharmaceuticals Incorporated's stock has gained approximately 70.39% over the past 52 weeks. The 50-day moving average sits at 1,401.44, while the 200-day moving average is 1,202.54.

Over the twelve months ended June 30, 2026, Oramed Pharmaceuticals Incorporated generated - - in revenue and converted that into 51.83B in net income, yielding earnings per share of 1,236.24. EBITDA reached -4.27B, while operating income came in at -4.30B.

As of June 30, 2026, Oramed Pharmaceuticals Incorporated holds 15.00B in cash and equivalents against 217.26M in total debt, resulting in a net debt position of -4.52B. Total book value stands at 94.10B, with working capital of 12.65B providing operational flexibility.

Oramed Pharmaceuticals Incorporated produced -1.54B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -572.93M in capital expenditures, free cash flow totaled -2.12B - equivalent to -51.60 per share.

Over the twelve months ended June 30, 2026, Oramed Pharmaceuticals Incorporated paid dividends of 75.48 per share. The dividend payout ratio of 5.97 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -3.60: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 8.54, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Oramed Pharmaceuticals Incorporated shareholders.

Oramed Pharmaceuticals Incorporated's most recent stock split took place on January 23, 2013 with a 12:1 split ratio.

As of June 30, 2026, Oramed Pharmaceuticals Incorporated has an Altman Z-Score of 2.23, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.